Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A carcinoma that arises from the ovary and is characterized by the presence of large malignant cells exhibiting neuroendocrine differentiation. The prognosis is poor.
No clinical trials have been registered for ovarian large-cell neuroendocrine carcinoma.
8 publications have been identified in PubMed for ovarian large-cell neuroendocrine carcinoma. Research spans Case Report / Case Series (57%) and Review / Meta-Analysis (43%).
Yamamoto K (2025). [PMID: 40176851](https://pubmed.ncbi.nlm.nih.gov/40176851/). *Gynecol Oncol Rep*. [Case Report / Case Series]
Yoon H (2025). [PMID: 41149460](https://pubmed.ncbi.nlm.nih.gov/41149460/). *Curr Oncol*. [Case Report / Case Series]
Mohsin M (2025). [PMID: 40108706](https://pubmed.ncbi.nlm.nih.gov/40108706/). *J Med Case Rep*. [Review / Meta-Analysis]
Faridzi AS (2025). [PMID: 39819883](https://pubmed.ncbi.nlm.nih.gov/39819883/). *Am J Case Rep*. [Case Report / Case Series]
Mantilidewi KI (2025). [PMID: 40490785](https://pubmed.ncbi.nlm.nih.gov/40490785/). *J Ovarian Res*. [Review / Meta-Analysis]
Wang M (2024). [PMID: 39091963](https://pubmed.ncbi.nlm.nih.gov/39091963/). *SAGE Open Med Case Rep*. [Case Report / Case Series]
Data assembled from 2 of 12 sources · Last updated Sep 20, 2026, 8:43 AM UTC
He Q (2024). [PMID: 39541042](https://pubmed.ncbi.nlm.nih.gov/39541042/). *Med Oncol*. [Review / Meta-Analysis]
AI-curated news mentioning ovarian large-cell neuroendocrine carcinoma
Updated Jul 28, 2026
Recent research highlights metastatic large cell neuroendocrine carcinoma as a rare cause of hypopituitarism. This discovery may influence future diagnostic and treatment approaches for patients presenting with pituitary dysfunction.
A case report and literature review on primary large cell neuroendocrine carcinoma of the pulmonary artery has been published, contributing to the understanding of this rare cancer type. The findings may inform future research and clinical approaches.
A recent publication discusses mixed large cell neuroendocrine carcinoma and adenocarcinoma of the cervix, highlighting its rarity and clinical significance. This research contributes to the understanding of this uncommon cancer type.